Properly valuing drug and biotechnology assets is essential for pharmaceutical enterprises, biotech companies, investors, and other healthcare stakeholders. Valuation provides vital insights to inform high-impact decisions including clinical trial continuation,…
Pharma Business Development and Licensing (BD&L) activities covering pharmaceutical licensing and partnering are integral to the growth strategy of pharma and biotech companies and their pipelines. In the evaluation of attractive…
In the pharmaceutical and biotechnology industry (referred to collectively as biopharma), almost all valuation and investment decisions decisions are based on DCF-based risk-adjusted net present value. Indeed, several other financial…
Several stakeholders who have an interest in pharmaceutical assets employ a multitude of methods to conduct valuations. Among various valuation methods, risk-adjusted NPV (rNPV) conducted using discounted cash flow analysis…